Taunia Markvicka

Taunia Markvicka is a declared insider at 3 companies (senior executive); the most frequent names are Pacira BioSciences, Inc., CorMedix Inc. and Cytocom, Inc. Over a trading history stretching from 12 July 2013 to 28 September 2021, the count stands at 17 filings.

The open-market side counts 4 purchases for €67k alongside 7 sales for €3.4M. Netting one side against the other leaves €3.3M of net selling. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 1 share grant and 5 option exercises.

The median purchase comes to €17k. Looking at 4 purchases old enough to measure, the stock rose over the following 90 days in 50% of cases; the median change was -4.6%. They describe history only and say nothing certain about the share price ahead.

Most recently, on 30 September 2021, the filings show a share grant in Cytocom, Inc. The last insider purchase was made public on 17 May 2017, 3,462 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.